1. A registry study of relapsed or refractory multiple myeloma pre‐exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38‐targeted monoclonal antibody therapy in England. Issue 3 (10th June 2021) Authors: Elsada, Ahmed; Zalin‐Miller, Amy; Knott, Craig; Caravotas, Leonidas Journal: EJHaem Issue: Volume 2:Issue 3(2021) Page Start: 493 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗